Insights into the platelet releasate

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2640-2646

  Coppinger, J A ^a   Maguire, Patricia B ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Angiogenesis; Atherosclerosis; Inflammatory and vasoactive proteins; Platelet releasate; Platelets; Proteomics; Secretion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIN; BETA 2 MICROGLOBULIN; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; CLOPIDOGREL; COFILIN; CYCLOPHILIN A; FIBRINOGEN RECEPTOR ANTAGONIST; GELATINASE A; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR 1; OSTEONECTIN; PADGEM PROTEIN; PHOSPHOGLYCERATE KINASE; PROFILIN; PROTEIN 14 3 3; PROTEIN ANTIBODY; RANTES; SOMATOMEDIN C; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D BINDING PROTEIN;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLEEDING; BLOOD VESSEL REACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; ENDOTHELIUM CELL; EXOSOME; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LYSOSOME; NONHUMAN; PARTICULATE MATTER; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SECRETORY GRANULE; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION;

EID: 34548787335     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662885     Document Type: Review

References (91)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): S419-20.
2. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94(11): 3791-9.
3. Fukami H, Holmsen H, Kowalska M, Niewiarowski S. In 4th Ed, Platelet secretion. Philadelphia, Lippincott Williams and Wilkins Co. 2001.
4. Foy M, Maguire PB. Recent advances in the characterisation of the platelet membrane by proteomics. Curr Pharm Des 2006; In Press.
5. George JN. Platelet immunoglobulin G: Its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood 1990; 76(5): 859-70.
6. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154(3): 485-90.
7. Levy-Toledano S, Caen JP, Breton-Gorius J, Rendu F, Cywiner-Golenzer C, Dupuy E, et al. Gray platelet syndrome: Alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med 1981; 98(6): 831-48.
8. Nurden AT, Kunicki TJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood 1982; 59(4): 709-18.
9. Gebrane-Younes J, Cramer E, Orcel L, Caen J. Gray platelet syndrome. Dissociation between abnormal sorting in megakaryocyte alpha-granules and normal sorting in Weibel-Palade bodies of endothelial cells. J Clin Invest 1993; 92(6): 3023-8.
10. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1(7): 1602-12.
11. Cramer EM, Savidge GF, Vainchenker W, Berndt MC, Pidard D, Caen JP, et al. Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 1990; 75(6): 1220-7.
12. Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J 1997; 29(2): 153-65.
13. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24(24): 2166-79.
14. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000; 19(7): 597-614.
15. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001; 193(12): 1341-9.
16. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev 1993; 7(1): 52-62.
17. Aulak KS, Donaldson VH, Coutinho M, Davis AE, 3rd. Cl-inhibitor: structure/function and biologic role. Behring Inst Mitt 1993(93): 204-13.
18. Krijgsveld J, Zaat SA, Meeldijk I, van Veelen PA, Fang G, Poolman B, et al. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletions products of CXC chemokines. J Biol Chem 2000; 275(27): 20374-81.
19. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22(9): 913-22.
20. Dubernard V, Arbeillo BB, Lemesle MB, Legrand C. Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vasc Biol 1997; 17(10): 2293-305.
21. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70(12): 6524-33.
22. Oh J, Bailin T, Fukai K, Feng GH, Ho L, Mao JI, et al. Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet 1996; 14(3): 300-6.
23. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, et al. Heterogeneity in storage pool deficiency: Studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54(6): 1296-319.
24. Zhen L, Jiang S, Feng L, Bright NA, Peden AA, Seymour AB, et al. Abnormal expression and subcellular distribution of subunit proteins of the AP-3 adaptor complex lead to platelet storage pool deficiency in the pearl mouse. Blood 1999; 94(1): 146-55.
25. Reed GL, Fitzgerald ML, Polgar J. Molecular mechanisms of platelet exocytosis: Insights into the "secrete" life of thrombocytes. Blood 2000; 96(10): 3334-42.
26. Martinson EA, Scheible S, Marx-Grunwitz A, Presek P. Secreted ADP plays a central role in thrombin-induced phospholipase D activation in human platelets. Thromb Haemost 1998; 80(6): 976-81.
27. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85(2): 341-8
28. Ware JA, Coller BS. Williams Haematology. New York: NcGraw, 1995.
29. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415(6868): 175-9.
30. Varnum SM, Covington CC, Woodbury RL, Petritis K, Kangas LJ, Abdullah MS, et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 2003; 80(1): 87-97.
31. Hewitt EW, Treumann A, Morrice N, Tatnell PJ, Kay J, Watts C. Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation. J Immunol 1997; 159(10): 4693-9.
32. Nakagawa S, Kumin S, Nitowsky HM. Studies on the activities and properties of lysosomal hydrolases in fractionated populations of human peripheral blood cells. Clin Chim Acta 1980; 101(1): 33-44.
33. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999; 82(2): 794-800.
34. Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coagul Fibrinolysis 1995; 6(4): 302-10.
35. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263(34): 18205-12.
36. Owens MR, Holme S, Cardinali S. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets. Thromb Res 1992; 66(2-3): 247-58.
37. Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective. Crit Rev Oncol Hematol 1999; 30(2): 111-42.
38. Heijnen HF, Debili N, Vainchencker W, Breton-Gorius J, Geuze HJ, Sixma JJ. Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood 1998; 91(7): 2313-25.
39. Rieu S, Geminard C, Rabesandratana H, Sainte-Marie J, Vidal M. Exosomes released during reticulocyte maturation bind to fibronectin via integrin alpha4beta1. Eur J Biochem 2000; 267(2): 583-90.
40. Peters PJ, Geuze HJ, Van der Donk HA, Slot JW, Griffith JM, Stam NJ, et al. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes. Eur J Immunol 1989; 19(8): 1469-75.
41. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete, antigen-presenting vesicles. J Exp Med 1996; 183(3): 1161-72.
42. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 1998; 4(5): 594-600
43. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004;31(1): 114-21.
44. Admyre C, Grunewald J, Thyberg J, Gripenback S, Tornling G, Eklund A, et al. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur Respir J 2003; 22(4): 578-83.
45. Clayton A, Turkes A, Dewitt S, Steadman R, Mason MD, Hallett MJB. Adhesion and signaling by B cell-derived exosomes: The role of integrins. Faseb J 2004; 18(9): 977-9.
46. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001; 166(12): 7309-18.
47. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987; 262(19): 9412-20.
48. Naaby-Hansen S, Waterfield MD, Cramer R. Proteomics-post-genomic cartography to understand gene function. Trends Pharmacol Sci 2001; 22(7): 376-84.
49. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21(6): 1037-53.
50. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999; 17(7): 676-82.
51. Griffin TJ, Aebersold R. Advances in proteome analysis by mass spectrometry. J Biol Chem 2001; 276(49): 45497-500.
52. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, et al. The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3(7): 1345-64.
53. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2(10): 1096-103.
54. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3(4): 311-26.
55. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103(6): 2096-104.
56. Garcia BA, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF. The platelet microparticle proteome. J Proteome Res 2005; 4(5): 1516-21
57. O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, et al. Towards complete analysis of the platelet proteome. Proteomics 2002; 2(3): 288-305.
58. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschemeyer J, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003; 278(13): 10963-72.
59. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7(2): 215-21.
60. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9(1): 61-7.
61. Celi A, Lorenzet R, Furie B, Furie BC. Platelet-leukocyte endothelial cell interaction on the blood vessel wall. Semin Hematol 1991;34(4):327-35.
62. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003; 9(6): 263-8.
63. Belton O, Duffy A, Toomey S, Fitzgerald D. Cyclooxygenase isoforms and platelet vessel wall interactions in the ApoE knockout mouse model of atherosclerosis. Circulation 2003; 108(24): 3017-23.
64. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15(4): 237-54.
65. Kozaki K, Kaminski WE, Tang J, Hollenbach S, Lindahl P, Sullivan C, et al. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am J Pathol 2002; 161(4): 1395-407.
66. Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278(8): 6187-93.
67. Baltus T. von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78(2): 435-41.
68. Kim HK, Song KS, Park YS, Kang YE, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer 2003; 39(2): 184-91.
69. Chan K, Spencer EM. Megakaryocytes endocytose insulin-like growth factor (IGF) I and IGF-binding protein-3: A novel mechanism directing them into alpha granules of platelets. Endocrinology 1998; 139(2): 559-65.
70. Huff T, Otto AM, Miller CS, Meier M, Hannappel E. Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J 2002; 16(7): 691-6
71. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 2004; 25(4):201-9.
72. Wang Y, Su X, Wu Z, Sheibani N. Thrombospondin-1 deficient mice exhibit an altered expression pattern of alternatively spliced PECAM-1 isoforms in retinal vasculature and endothelial cells. J Cell Physiol 2005; 204(1): 352-61.
73. Zhou J, Rothman VL, Sargiannidou I, Dimitrov S, Qiu C, Smith E, el al. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J Cell Biochem 2004; 92(1): 125-46.
74. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, et al. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001; 8(2): 141-8.
75. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94(2): 663-8.
76. Lawler K, Meade G, O'Sullivan G, Kenny D. Shear stress modulates the interaction of platelet-secreted matrix proteins with tumor cells through the integrin alphavbeta3. Am J Physiol Cell Physiol 2004; 287(5): C1320-7.
77. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62(10): 2824-33.
78. Talley JD. Clinical trials of glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2001; 14(2): 129-42.
79. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36(5): 1514-9.
80. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103(2): 201-6.
81. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridgng mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187(3): 329-39.
82. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000; 97(13): 7458-63.
83. Veillard NP, Steffens S, Burger F, Pelli G, Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol 2004; 24(12): 2339-44.
84. Massberg S, Vogt F, Dickfeld T, Brand K, Page.S, Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res 2003; 110(4): 187-94.
85. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252(4): 283-94.
86. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors. Circulation 2002; 106(15): 1962-7.
87. Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC, et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J 2002; 143(2):235-41.
88. Ludlum CA, Bolton AE, Moore S, Cash JD. New rapid method for diagnosis of deep venous thrombosis. Lancet 1975; 2: 259-60.
89. Butler GS, Overall CM. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr Pharm Des 2007; 13(3): 263-70.
90. Tosatto SC, Toppo S. Large-scale prediction of protein structure and function from sequence. Curr Pharm Des 2006; 12(17): 2067-86.
91. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11(18): 2331-65.